Joint effects of multiple sleep characteristics on breast cancer progression by menopausal status

Prognostic Value of Anti-Chlamydia Trachomatis IgG in Breast Cancer and the Modification Effects of Pro-Inflammatory Cytokines: A 13-Year Prospective Cohort Study

Purpose

Chlamydia trachomatis (C. trachomatis) is associated with several gynecological tumors; yet its prognostic role in breast cancer remains unclear. Thus, we investigated the prognostic role of anti-C. trachomatis immunoglobulin G (IgG) in breast cancer patients and the modification effects of pro-inflammatory cytokines.

Methods

The serum levels of C. trachomatis IgG and four pro-inflammatory cytokines were measured. Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), including product terms to assess the modification effects of pro-inflammatory cytokines on the association between C. trachomatis IgG and breast cancer prognosis.

Results

From 2008 to 2018, 1121 breast cancer patients were recruited and followed up until December 31, 2021, with a median follow-up time of 63.91 months (interquartile range: 39.16-90.08 months). Patients positive for C. trachomatis IgG showed HRs of 1.09 (95% CI, 0.67-1.78) for overall survival (OS) and 1.24 (0.87-1.78) for progression-free survival (PFS), compared to those who were negative. These associations became statistically significant in women aged 50 years or younger (HR=1.43, 95% CI=0.79-2.58 for OS; HR=1.79, 95% CI=1.16-2.77 for PFS). Positive C. trachomatis IgG serology was associated with adverse prognostic effects among patients with higher levels of pro-inflammatory cytokines (IL-6, TNF-α, IL-8, and IL-1β), but with favorable prognostic effects for those with low levels. These interactions were particularly significant in those aged 50 years or younger.

Conclusion

In breast cancer patients younger than 50 years of age or with higher levels of pro-inflammatory cytokines, C. trachomatis infection appeared to have a negative prognostic impact. These findings highlight the significance of C. trachomatis in predicting prognosis and personalized therapy for breast cancer patients.

Sleep duration and mortality among breast cancer survivors in the Western New York Exposures and Breast Cancer (WEB) Study

PURPOSE

There is increasing evidence that sleep duration may affect breast cancer survival through effects on circadian function, influencing disease progression. However, further investigation of this association is needed.

METHODS

In a population-based, prospective cohort study of women from the Western New York Exposures and Breast Cancer Study, we examined mortality outcomes with invasive breast cancer identified using the National Death Index. Cox proportion hazards ratios with 95% confidence intervals were used to estimate risk of all-cause (AC) and breast cancer-specific (BC) mortality associated with self-reported usual sleep duration with adjustment for age, race/ethnicity, years of education, body mass index (BMI), menopausal status, pack-years of smoking, tumor stage, and estrogen-receptor (ER) status. We further examined associations within strata of BMI, tumor stage, menopausal status, and ER status.

RESULTS

A sample of 817 patients with breast cancer were followed for a median of 18.7 years, during which 339 deaths were reported, including 132 breast cancer-specific deaths. Those who reported shorter or longer sleep tended to have a slightly higher BMI, to be less proportionately non-Hispanic White, to report a previous history of benign breast disease, and to have consumed more alcohol during their lifetime. We found no significant associations between sleep duration and AC or BC mortality, including within stratified analyses.

CONCLUSION

Sleep duration was not associated with either AC or BC mortality including within strata of BMI, tumor stage, menopausal status, or ER status.

Circadian rhythm disrupting behaviours and cancer outcomes in breast cancer survivors: a systematic review

PURPOSE

Circadian rhythm disruptors (e.g., night-shift work) are risk factors for breast cancer, however studies on their association with prognosis is limited. A small but growing body of research suggests that altered sleep patterns and eating behaviours are potential mechanistic links between circadian rhythm disruptors and breast cancer. We therefore systematically summarised literature examining the influence of circadian rhythm disrupting behaviours on cancer outcomes in women with breast cancer.

METHODS

A systematic search of five databases from inception to January 2021 was conducted. Original research published in English, assessing the relationship between post-diagnosis sleep patters and eating behaviours, and breast cancer outcomes were considered. Risk of bias was assessed using the Newcastle-Ottawa Assessment Scale for Cohort Studies.

RESULTS

Eight studies published original evidence addressing sleep duration and/or quality (k = 7) and, eating time and frequency (k = 1). Longer sleep duration (≥ 9 h versus [referent range] 6-8 h) was consistently associated with increased risk of all outcomes of interest (HR range: 1.37-2.33). There was limited evidence to suggest that measures of better sleep quality are associated with lower risk of all-cause mortality (HR range: 0.29-0.97). Shorter nightly fasting duration (< 13 h versus ≥ 13 h) was associated with higher risk of all breast cancer outcomes (HR range: 1.21-1.36).

CONCLUSION

Our review suggests that circadian rhythm disrupting behaviours may influence cancer outcomes in women with breast cancer. While causality remains unclear, to further understand these associations future research directions have been identified. Additional well-designed studies, examining other exposures (e.g., light exposure, temporal eating patterns), biomarkers, and patient-reported outcomes, in diverse populations (e.g., breast cancer subtype-specific, socio-demographic diversity) are warranted.

Factors Affecting Sleep Quality of Breast Cancer Patients with Chemotherapy

BACKGROUND: Poor sleep quality becomes the effect of chemotherapy in breast cancer patients. AIM: This study aimed to examine the factors that influence breast cancer patients’ sleep quality undergoing chemotherapy. METHODS: This research used an observational method with cross-sectional design. There were 26 breast cancer patients undergoing chemotherapy at Djojonegoro Regional Hospital in Temanggung, Central Java. The characteristics of the respondent are recorded, including the demographic characteristics, respondents’ sleep quality, and the physiological status data of the respondent. The researchers use the Pittsburgh Sleep Quality Index (PSQI) to measure sleep quality. Data were analyzed using Kendall’s Tau and Spearman’s rank correlation test and the Pearson Product-Moment Correlation test. RESULTS: The result showed that breast cancer patients’ sleep quality is classified as poor with PSQI score of 10.96 ± 3.13. The average age of the respondent was 50.08 ± 7.31 years. The major characteristic of the respondent were 80.77% had married, 42.30% had elementary education, 61.54% did not work, and 61.54% had Rp 0, - income. Based on breast cancer patients undergoing chemotherapy, the respondents lived in rice field environment (42.30%), diagnosed with breast cancer <1 year (69.23%), had <1 year chemotherapy (96.15%), had under mastectomy on the left breast (80.76%), and underwent chemotherapy as much as 7.23 ± 4.80 times. Based on sleep quality, the respondents lived with nuclear family (61.54%), had no comorbidities (76.92%), did not consume other drugs (100%), did not consume sleeping pills (80.76%), and used lights during sleep (65.38%). There is a correlation between sleep quality and age and with whom the respondent lives in the same house. CONCLUSION: It was concluded that breast cancer patients undergoing chemotherapy had poor sleep quality, and the factors related to sleep quality were age and with whom the respondent lived in the same house.